Cargando…

Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial

Bile acid sequestrants (BAS) lower plasma low density lipoprotein levels and improve glycemic control. Colestimide, a BAS, has been claimed by computed tomography to reduce liver fat. Therefore, we examined the efficacy of colesevelam, a potent BAS, to decrease liver fat in patients with biopsy-prov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le, Thuy-Anh, Chen, Joshua, Changchien, Christopher, Peterson, Michael R, Kono, Yuko, Patton, Heather, Cohen, Benjamin L, Brenner, David, Sirlin, Claude, Loomba, Rohit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Subscription Services, Inc., A Wiley Company 2012
Materias:	Steatohepatitis/Metabolic Liver Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400720/ https://www.ncbi.nlm.nih.gov/pubmed/22431131 http://dx.doi.org/10.1002/hep.25731

Ejemplares similares

Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)
por: Loomba, Rohit, et al.
Publicado: (2015)

Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study
por: Loomba, Rohit, et al.
Publicado: (2014)

Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice
por: Locatelli, Irene, et al.
Publicado: (2014)

Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
por: Decaris, Martin L., et al.
Publicado: (2016)

IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice
por: Harley, Isaac TW, et al.
Publicado: (2014)

Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
por: Hall, Zoe, et al.
Publicado: (2017)

Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance
por: Kozlitina, Julia, et al.
Publicado: (2011)

Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis
por: Smagris, Eriks, et al.
Publicado: (2015)

A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis
por: Phatak, Pradyumna, et al.
Publicado: (2010)

Apolipoprotein CIII Overexpressing Mice Are Predisposed to Diet-Induced Hepatic Steatosis and Hepatic Insulin Resistance
por: Lee, Hui-Young, et al.
Publicado: (2011)

Role of Patatin-Like Phospholipase Domain-Containing 3 on Lipid-Induced Hepatic Steatosis and Insulin Resistance in Rats
por: Kumashiro, Naoki, et al.
Publicado: (2013)

The small molecule, genistein, increases hepcidin expression in human hepatocytes
por: Zhen, Aileen W, et al.
Publicado: (2013)

Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample
por: Yang, Xu, et al.
Publicado: (2015)

Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: A randomized controlled trial
por: Koopman, Karin E, et al.
Publicado: (2014)

Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice
por: Gariani, Karim, et al.
Publicado: (2015)

Ring finger protein20 regulates hepatic lipid metabolism through protein kinase A-dependent sterol regulatory element binding protein1c degradation
por: Lee, Jae Ho, et al.
Publicado: (2014)

Vertical sleeve gastrectomy activates GPBAR‐1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice
por: Ding, Lili, et al.
Publicado: (2016)

Hypothalamic kappa opioid receptor mediates both diet‐induced and melanin concentrating hormone–induced liver damage through inflammation and endoplasmic reticulum stress
por: Imbernon, Monica, et al.
Publicado: (2016)

Identification of p38 MAPK and JNK as new targets for correction of Wilson disease‐causing ATP7B mutants
por: Chesi, Giancarlo, et al.
Publicado: (2016)

Metabolic profiling of fatty liver in young and middle‐aged adults: Cross‐sectional and prospective analyses of the Young Finns Study
por: Kaikkonen, Jari E., et al.
Publicado: (2016)

Activation of the c‐Jun N‐terminal kinase pathway aggravates proteotoxicity of hepatic mutant Z alpha1‐antitrypsin
por: Pastore, Nunzia, et al.
Publicado: (2017)

Human macrophage ferroportin biology and the basis for the ferroportin disease
por: Sabelli, Manuela, et al.
Publicado: (2017)

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
por: Anstee, Quentin M., et al.
Publicado: (2023)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis
por: Yan, Tingting, et al.
Publicado: (2023)

Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice
por: Kim, Kyung Eun, et al.
Publicado: (2023)

Resting and Exercise Energy Metabolism After Liver Transplantation for Nonalcoholic Steatohepatitis
por: Levitsky, Josh, et al.
Publicado: (2017)

Ultra‐high‐field magnetic resonance spectroscopy in non‐alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non‐alcoholic steatohepatitis and advanced fibrosis
por: Traussnigg, Stefan, et al.
Publicado: (2017)

Characterization of Gut Microbiome in Liver Transplant Recipients With Nonalcoholic Steatohepatitis
por: Satapathy, Sanjaya K., et al.
Publicado: (2020)

Clinical practice gaps and challenges in non‐alcoholic steatohepatitis care: An international physician needs assessment
por: Lazure, Patrice, et al.
Publicado: (2022)

Immune Features of Disparate Liver Transplant Outcomes in Female Hispanics With Nonalcoholic Steatohepatitis
por: Sosa, Rebecca A., et al.
Publicado: (2023)

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

The endothelial function biomarker soluble E‐selectin is associated with nonalcoholic fatty liver disease
por: Simons, Nynke, et al.
Publicado: (2020)

Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice
por: Hartmann, Phillipp, et al.
Publicado: (2022)

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
por: Allende, Daniela S, et al.
Publicado: (2021)

Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease
por: Flores‐Guerrero, Jose L., et al.
Publicado: (2021)

MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis
por: Loomba, Rohit
Publicado: (2021)

Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity
por: Pavlides, Michael, et al.
Publicado: (2017)

Serum coding and non‐coding RNAs as biomarkers of NAFLD and fibrosis severity
por: Di Mauro, Stefania, et al.
Publicado: (2019)

Prescription of statins in suspected non‐alcoholic fatty liver disease and high cardiovascular risk, a population‐based study
por: van den Berg, Eline H., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7d8inpr5u7r7d0obfm1qo8ak2l